Company Overview and News

 
Jeff Bezos-backed cancer startup is said to seek to raise US$1 billion

2018-04-19 nzherald.co.nz
Grail Inc., the cancer-detection startup backed by the world's two richest men, is seeking to raise about US$1 billion ($1.3b) to boost growth ahead of its planned initial public offering in Hong Kong, according to people familiar with the matter.
Upvote Downvote

 
Bristol-Myers Reports Positive Data in NSCLC Trial on Opdivo

2018-04-16 zacks
Bristol-Myers Squibb Company (BMY - Free Report) announced results from the phase III trial, CheckMate -078 trial on blockbuster drug Opdivo in a number of people, the majority of whom were from China.
Upvote Downvote

 
Can Solid Overall Growth Drive Illumina's (ILMN) Q1 Earnings?

2018-04-12 zacks
Illumina, Inc. (ILMN - Free Report) is slated to report first-quarter 2018 results, after markets close on Apr 24. Last quarter, the company delivered a positive earnings surprise of 18.03% with the average earnings beat being 13% for three of the trailing four quarters. Let's see how things are shaping up prior to this announcement.
Upvote Downvote

 
Your Daily Pharma Scoop: vTv Therapeutics Plunges, Spectrum Provides Updated Data, Selecta Sees Pullback On Data

2018-04-11 seekingalpha
Today we will discuss vTv Therapeutics (NASDAQ:VTVT), which has seen three quarters of its market capitalization wiped off after the failure of a late-stage Alzheimer’s study. The failure once again highlights the fact that Alzheimer’s remains a difficult to treat area.
Upvote Downvote

 
Pacific Biosciences: A Shovel Supplier To The Genomics Megatrend

2018-04-10 seekingalpha
Pacific Biosciences of California is one of the main three producers of genome sequencing machines, alongside Illumina and privately-held Oxford Nanopore Technologies.
Upvote Downvote

 
Loxo, Illumina to partner for diagnostic tool targeting cancer

2018-04-10 channelnewsasia
REUTERS: Drug developer Loxo Oncology said on Tuesday it is partnering with genetic testing company Illumina Inc on a diagnostic tool that will work with Loxo's larotrectinib and another one of its experimental cancer drugs, across tumor types.
Upvote Downvote

 
UPDATE 1-Loxo, Illumina to partner for diagnostic tool targeting cancer

2018-04-10 reuters
(Reuters) - Drug developer Loxo Oncology said on Tuesday it is partnering with genetic testing company Illumina Inc on a diagnostic tool that will work with Loxo’s larotrectinib and another one of its experimental cancer drugs, across tumor types.
Upvote Downvote

 
Loxo and Illumina in partnership over diagnostic for cancer drug

2018-04-10 reuters
(Reuters) - Loxo Oncology (LOXO.O) is partnering with genetic testing company Illumina Inc (ILMN.O) to use Illumina’s diagnostic tool alongside larotrectinib, the drug developer’s potential blockbuster drug, the companies said on Tuesday.
Upvote Downvote

 
ILMN / Illumina, Inc. DEF 14A

2018-04-06 sec.gov
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy S
Upvote Downvote

 
ILMN / Illumina, Inc. DEFA14A

2018-04-06 sec.gov
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the
Upvote Downvote

 
Genome Sequencing Roundup

2018-04-02 seekingalpha
After my recent review of genome sequencing giant Illumina (ILMN), interaction with some of the commenters made me realize that it might be a good idea to analyze the other companies in the space a bit more closely. As the core sequencing technology varies from company to company, it is a good idea to have at least a basic grasp of the intellectual property before moving on to analyze the financials.
Upvote Downvote

 
Illumina: Sequencing Profits

2018-03-26 seekingalpha
Growth potential looks secure for the foreseeable future with a projected 13%-14% increase in revenue in 2018.
Upvote Downvote

 
Why the National Institute of Health New Budget Looks So Promising

2018-03-26 247wallst
According to a recent analyst report by Janney, the National Institute of Health (NIH) budget that was approved last Friday could be a big boost for some select biopharma stocks. The budget is said to be the best in 15 years and that the momentum is strong under the president and Republican leadership.
Upvote Downvote

 
Illumina Banks on Product Launches & Strategic Partnerships

2018-03-13 zacks
On Mar 12, we issued an updated research report on Illumina, Inc. (ILMN - Free Report) , a Zacks Rank #3 (Hold) stock.
Upvote Downvote

 
ILMN / Illumina, Inc. null

2018-03-09 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C0Y(# @;V)J#3P\+TQI;F5AF4@-C(O5'EP92]84F5F+U=;,2 R(#%=/CYS=')E86T-"FC>8F)D$&!@ M8F#R A(,4X $XWT@P1(")-A_ XE/$0Q,C P'0+(,C.C$?\;)?P "# #8N0?D M#0IE;F1S=')E86T-96YD;V)J#7-T87)T>')E9@T*, T*)25%3T8-"B @(" @ M(" @#0HV,2 P(&]B:@T\/"]#(#8Y+T9I;'1E
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 452327109